Cell Source, Inc.

CLCS · OTC
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$4,771-$5,321-$5,168-$5,472
Dep. & Amort.$0$0$285,300,000$731,502,000
Deferred Tax$0$0-$285,300,000-$731,502,000
Stock-Based Comp.$0$445$78$419
Change in WC$1,761$2,218$1,564$701
Other Non-Cash$326$309$388$973
Operating Cash Flow-$2,684-$2,348-$3,139-$3,379
Investing Activities
PP&E Inv.$0$0$0$0
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$0$0$0$0
Investing Cash Flow$0$0$0$0
Financing Activities
Debt Repay.$834$1,627$3,296$2,283
Stock Issued$1,792$800$0$0
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$111$520-$28$944
Financing Cash Flow$2,737$2,147$3,268$3,227
Forex Effect$0$0$0$0
Net Chg. in Cash$52-$200$130-$152
Supplemental Information
Beg. Cash$22$223$93$245
End Cash$75$22$223$93
Free Cash Flow-$2,684-$2,348-$3,139-$3,379
Cell Source, Inc. (CLCS) Financial Statements & Key Stats | AlphaPilot